MedTrace Logo

TI-001 (Intranasal Oxytocin) for Treatment of High Frequency Episodic Migraine and Chronic Migraine

NCT01839149 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 240

Last updated 2016-05-13

No results posted yet for this study

Summary

This study evaluates the use of oxytocin, given as a nasal spray, for treatment of high frequency episodic migraine and chronic migraine.

Conditions

  • High Frequency Episodic Migraine and Chronic Migraine

Interventions

DRUG

TI-001

TI-001 is intranasal oxytocin

DRUG

Placebo

Sponsors & Collaborators

  • Trigemina, Inc

    lead INDUSTRY

Principal Investigators

  • Raquel Izumi, PhD · Trigemina, Inc

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-05-31
Primary Completion
2015-10-31
Completion
2016-01-31

Countries

  • Australia
  • Chile
  • New Zealand

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01839149 on ClinicalTrials.gov